JP5449134B2 - 未熟児合併症の治療及び／又は予防の方法と製品 - Google Patents

未熟児合併症の治療及び／又は予防の方法と製品 Download PDF

Info

Publication number
JP5449134B2
JP5449134B2 JP2010504018A JP2010504018A JP5449134B2 JP 5449134 B2 JP5449134 B2 JP 5449134B2 JP 2010504018 A JP2010504018 A JP 2010504018A JP 2010504018 A JP2010504018 A JP 2010504018A JP 5449134 B2 JP5449134 B2 JP 5449134B2
Authority
JP
Japan
Prior art keywords
igfbp
igf
composition
birth
preterm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010504018A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010524928A (ja
JP2010524928A5 (https=
Inventor
アン・ヘルストレム
カタリーナ・レーフクヴィスト
ロイス・スミス
Original Assignee
プレーマクレ・アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレーマクレ・アクチエボラーグ filed Critical プレーマクレ・アクチエボラーグ
Publication of JP2010524928A publication Critical patent/JP2010524928A/ja
Publication of JP2010524928A5 publication Critical patent/JP2010524928A5/ja
Application granted granted Critical
Publication of JP5449134B2 publication Critical patent/JP5449134B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010504018A 2007-04-18 2008-04-18 未熟児合併症の治療及び／又は予防の方法と製品 Active JP5449134B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92396307P 2007-04-18 2007-04-18
US60/923,963 2007-04-18
PCT/SE2008/050441 WO2008130315A1 (en) 2007-04-18 2008-04-18 Method and product for treatment and/or prevention of complications of prematurity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013189927A Division JP2013249317A (ja) 2007-04-18 2013-09-13 未熟児合併症の治療及び／又は予防の方法と製品

Publications (3)

Publication Number Publication Date
JP2010524928A JP2010524928A (ja) 2010-07-22
JP2010524928A5 JP2010524928A5 (https=) 2011-05-12
JP5449134B2 true JP5449134B2 (ja) 2014-03-19

Family

ID=39875739

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010504018A Active JP5449134B2 (ja) 2007-04-18 2008-04-18 未熟児合併症の治療及び／又は予防の方法と製品
JP2013189927A Pending JP2013249317A (ja) 2007-04-18 2013-09-13 未熟児合併症の治療及び／又は予防の方法と製品

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013189927A Pending JP2013249317A (ja) 2007-04-18 2013-09-13 未熟児合併症の治療及び／又は予防の方法と製品

Country Status (5)

Country Link
US (3) US8518877B2 (https=)
EP (1) EP2148695B1 (https=)
JP (2) JP5449134B2 (https=)
CN (1) CN101969983B (https=)
WO (1) WO2008130315A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013249317A (ja) * 2007-04-18 2013-12-12 Premacure Ab 未熟児合併症の治療及び／又は予防の方法と製品

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6284341B2 (ja) 2012-10-24 2018-02-28 国立大学法人東京農工大学 未熟児網膜症の治療又は予防剤、未熟児網膜症の検査方法及び未熟児網膜症の治療又は予防物質のスクリーニング方法
US9510055B2 (en) 2013-01-23 2016-11-29 Sonos, Inc. System and method for a media experience social interface
US20150220498A1 (en) 2014-02-05 2015-08-06 Sonos, Inc. Remote Creation of a Playback Queue for a Future Event
US9679054B2 (en) 2014-03-05 2017-06-13 Sonos, Inc. Webpage media playback
US20150324552A1 (en) 2014-05-12 2015-11-12 Sonos, Inc. Share Restriction for Media Items
US20150356084A1 (en) 2014-06-05 2015-12-10 Sonos, Inc. Social Queue
US9874997B2 (en) 2014-08-08 2018-01-23 Sonos, Inc. Social playback queues
EP3114852A1 (en) 2014-09-24 2017-01-11 Sonos Inc. Social media queue
WO2016049342A1 (en) 2014-09-24 2016-03-31 Sonos, Inc. Social media connection recommendations based on playback information
US9959087B2 (en) 2014-09-24 2018-05-01 Sonos, Inc. Media item context from social media
US10645130B2 (en) 2014-09-24 2020-05-05 Sonos, Inc. Playback updates
US9690540B2 (en) 2014-09-24 2017-06-27 Sonos, Inc. Social media queue
US9860286B2 (en) 2014-09-24 2018-01-02 Sonos, Inc. Associating a captured image with a media item
US9667679B2 (en) 2014-09-24 2017-05-30 Sonos, Inc. Indicating an association between a social-media account and a media playback system
US9723038B2 (en) 2014-09-24 2017-08-01 Sonos, Inc. Social media connection recommendations based on playback information
WO2018093797A1 (en) * 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
EP4663184A3 (en) * 2017-09-11 2026-03-18 Oak Hill Bio Limited Compositions for reducing the incidence of bpd
WO2019099560A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
CN114126640B (zh) * 2019-05-28 2024-10-29 爱儿安制药有限公司 治疗视网膜病变的组合物和方法
WO2023242442A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Method of maturing/differentiating neurons and/or modulating the vagus nerve
WO2023242440A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants
EP4598630A1 (en) * 2022-10-04 2025-08-13 Oak Hill Bio Limited Method of treating neonates with igf-1 complex
WO2024160999A1 (en) * 2023-02-03 2024-08-08 Oak Hill Bio Limited Treatment of kidney injury with igf-1 complex
WO2024170612A1 (en) * 2023-02-14 2024-08-22 Oak Hill Bio Limited Treatment of healing dysregulation in gi tissue

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
JPH07508025A (ja) * 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
DE60143858D1 (de) 2000-11-28 2011-02-24 Premacure Ab Reduzierung DES RISIKOS FÜR KOMPLIKATIONEN BEI FRÜHGEBURTEN
EP1906969A4 (en) * 2005-07-15 2009-07-29 Childrens Medical Center METHOD FOR TREATING AND DIAGNOSIS OF COMPLICATIONS IN AN EARLY BIRTH
EP2148695B1 (en) * 2007-04-18 2014-10-15 Premacure AB Method and product for treatment and/or prevention of complications of prematurity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013249317A (ja) * 2007-04-18 2013-12-12 Premacure Ab 未熟児合併症の治療及び／又は予防の方法と製品

Also Published As

Publication number Publication date
JP2013249317A (ja) 2013-12-12
US9463222B2 (en) 2016-10-11
EP2148695A1 (en) 2010-02-03
EP2148695B1 (en) 2014-10-15
CN101969983B (zh) 2014-11-05
JP2010524928A (ja) 2010-07-22
US8518877B2 (en) 2013-08-27
EP2148695A4 (en) 2013-01-16
CN101969983A (zh) 2011-02-09
WO2008130315A1 (en) 2008-10-30
US20130310316A1 (en) 2013-11-21
US20100204101A1 (en) 2010-08-12
US20150216943A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
JP5449134B2 (ja) 未熟児合併症の治療及び／又は予防の方法と製品
JP5089443B2 (ja) 未熟児合併症のリスクの決定および治療
Velloso Regulation of muscle mass by growth hormone and IGF‐I
Wren et al. Ghrelin enhances appetite and increases food intake in humans
Petrie Metformin beyond type 2 diabetes: Emerging and potential new indications
Roberts et al. Distinct actions of insulin-like growth factors (IGFs) on placental development and fetal growth: lessons from mice and guinea pigs
Giustina et al. Insulin and GH–IGF-I axis: endocrine pacer or endocrine disruptor?
AU2002239560A1 (en) Determination of risk and treatment of complications of prematurity
IL174209A (en) Use of igf-1 for manufacture of a medicament for use in treatment of igf-1 deficiency
Kiess et al. Leptin as a metabolic regulator during fetal and neonatal life and in childhood and adolescence.
BR112020004760A2 (pt) métodos e composições para tratamento de doenças pulmonares crônicas
GLUCKMAN Insulin-like growth factors and their binding
Skottner Biosynthesis of growth hormone and insulin-like growth factor-I and the regulation of their secretion
Engel Deciphering the role of insulin and IGF-1 in brain aging, Alzheimer’s disease, and vascular dementia
Maiteeg et al. Response to Recombinant Human Growth Hormone Therapy in Libyan Children with Growth Hormone Deficiency in Misurata
ES2355470T3 (es) Reducción del riesgo de complicaciones de la prematuridad.
Cianfarani Growth and Growth Factors
Knüpfera et al. Insulin-Like Growth Factor/Growth Hormone Axis in Intrauterine Growth and Its Role in Intrauterine Growth Retardation
Deschepper et al. Bibliography Current World Literature
van der Kaay et al. GH-IGF-IGFBP Axis and Metabolic Profile in Short Children Born Small for Gestational Age
EA044079B1 (ru) Способы и композиции, предназначенные для лечения хронических заболеваний легких
Encuentro et al. Low birth weight and endocrine dysfunction in postnatal life
Van Gool et al. Free Communications
LIM ABSENCE OF MYOSTATIN IMPROVES

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130913

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131224

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5449134

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250